At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRVO CervoMed
Not Yet Opened 01-07 16:00:00 EST
7.95
+0.41
+5.37%
盘后7.95
+0.000.00%
19:49 EST
High7.96Low7.61Vol29.73K
Open7.61D1 Closing7.55Amplitude4.62%
Mkt Cap73.56MTradable Cap39.23MTotal Shares9.25M
T/O231.41KT/O Rate0.60%Tradable Shares4.93M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CervoMed Showcases Pipeline Progress and Neflamapimod’s Promise in Brain Disorders
Reuters  ·  06:49
CervoMed Showcases Pipeline Progress and Neflamapimod’s Promise in Brain Disorders
CervoMed Initiated at Overweight by Cantor Fitzgerald
Dow Jones  ·  2025-12-18
CervoMed Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Initiates Coverage on CervoMed With Overweight Rating
MT Newswires Live  ·  2025-12-18
Cantor Fitzgerald Initiates Coverage on CervoMed With Overweight Rating
CervoMed Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Dow Jones  ·  2025-12-18
CervoMed Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
CervoMed Inc. Files Initial Statement of Beneficial Ownership for Director David Quigley
Reuters  ·  2025-12-06
CervoMed Inc. Files Initial Statement of Beneficial Ownership for Director David Quigley
CervoMed Inc - to Initiate Phase 3 Trial in Dlb Patients in 2026
THOMSON REUTERS  ·  2025-12-05
CervoMed Inc - to Initiate Phase 3 Trial in Dlb Patients in 2026
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
GlobeNewswire  ·  2025-12-05
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
CervoMed Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  2025-12-02
CervoMed Is Maintained at Buy by D. Boral Capital
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
GlobeNewswire  ·  2025-12-02
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
GlobeNewswire  ·  2025-11-24
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
CervoMed Executives Make Bold Moves with Major Stock Purchases!
TIPRANKS  ·  2025-11-20
CervoMed Executives Make Bold Moves with Major Stock Purchases!
CervoMed Chief Commercial and Business Officer Matthew Winton Reports Acquisition of Common Shares
Reuters  ·  2025-11-19
CervoMed Chief Commercial and Business Officer Matthew Winton Reports Acquisition of Common Shares
Director and 10% Owner Sylvie Gregoire Acquires Common Shares of Cervomed Inc
Reuters  ·  2025-11-17
Director and 10% Owner Sylvie Gregoire Acquires Common Shares of Cervomed Inc
CervoMed CEO John J. Alam Reports Acquisition of Common Shares
Reuters  ·  2025-11-17
CervoMed CEO John J. Alam Reports Acquisition of Common Shares
CervoMed Executives Make Bold Moves with Significant Stock Purchases!
TIPRANKS  ·  2025-11-14
CervoMed Executives Make Bold Moves with Significant Stock Purchases!
CervoMed CFO William Robert Elder Reports Acquisition of Common Shares
Reuters  ·  2025-11-13
CervoMed CFO William Robert Elder Reports Acquisition of Common Shares
CervoMed’s Strategic Advancements and Clinical Trial Developments Drive Buy Rating
TIPRANKS  ·  2025-11-12
CervoMed’s Strategic Advancements and Clinical Trial Developments Drive Buy Rating
CervoMed Is Maintained at Buy by D. Boral Capital
Dow Jones  ·  2025-11-11
CervoMed Is Maintained at Buy by D. Boral Capital
Canaccord Genuity Sticks to Their Buy Rating for CervoMed (CRVO)
TIPRANKS  ·  2025-11-11
Canaccord Genuity Sticks to Their Buy Rating for CervoMed (CRVO)
CervoMed price target lowered to $19 from $20 at Roth Capital
TIPRANKS  ·  2025-11-11
CervoMed price target lowered to $19 from $20 at Roth Capital

Introduction

Company Name.
CervoMed
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Issue price:
--